Share ownership Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-21 pm EST			5-day change	1st Jan Change
5.840 ^USD	+2.82%		-4.42%	-5.04%

Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM
Jan. 12	Myriad Genetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 and 2026	CI

Share class: Myriad Genetics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	91,035,230	89,198,688 ( 97.98 %)	0	97.98 %

Major shareholders: Myriad Genetics, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 15.06 %	14,041,203	15.06 %	86 M $
Vanguard Fiduciary Trust Co. 8.456 %	7,882,515	8.456 %	48 M $
STATE STREET CORPORATION 5.339 %	4,976,492	5.339 %	31 M $
Glenview Capital Management LLC 5.301 %	4,941,058	5.301 %	30 M $
Millennium Management LLC 5.094 %	4,748,327	5.094 %	29 M $
Glenview Capital Management LLC 4.921 %	4,587,407	4.921 %	28 M $
D.E. Shaw & Co., Inc. 4.891 %	4,559,136	4.891 %	28 M $
Morgan Stanley Capital Services LLC 3.88 %	3,616,925	3.88 %	22 M $
Jacobs Levy Equity Management, Inc. 2.621 %	2,442,912	2.621 %	15 M $
Geode Capital Management LLC 2.387 %	2,225,169	2.387 %	14 M $
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	84.54%
Other	12.88%
State Street Corp.	5.34%
Individuals	4.78%
Schweizerische Nationalbank	0.19%
Governments	0.08%
Manulife Financial Corp.	0.03%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	91.4%
Individuals	4.78%
United Kingdom	3.64%
Canada	2.24%
Australia	1.74%
France	1.27%
Luxembourg	1.25%
Denmark	0.4%
Sweden	0.37%
Switzerland	0.23%
Hong Kong	0.2%
Ireland	0.17%
Singapore	0.05%
Germany	0.05%
Norway	0.02%
Puerto Rico	0.01%
China	0.01%
United Arab Emirates	0.01%

Based on 1000 largest holdings

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company